Yahoo Finance • 2 days ago
What Happened? A number of stocks jumped in the afternoon session after confidence in the artificial intelligence market was renewed, pushing both the S&P 500 and Nasdaq to new all-time intraday highs. The rebound was led by chipmaker Nv... Full story
Yahoo Finance • 2 days ago
BALA CYNWYD, Pa., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ack... Full story
Yahoo Finance • 4 days ago
Roche, in collaboration with KlinRisk, Inc, has received CE-mark for the first AI-based risk stratification tool for assessment of progressive decline in kidney function.This tool will be launched as part of Roche’s new chronic kidney dise... Full story
Yahoo Finance • 7 days ago
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study1First and only combination therapy for the first-line maintenance treatment of ES-SCLC, which is critical to he... Full story
Yahoo Finance • 7 days ago
F. Hoffmann-La Roche Ltd Basel, 3 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Dr. Claudia Süssmuth Dyckerhoff has decided not to stand for re-election as a member of the Roche Board of Directors at the Annual Ge... Full story
Yahoo Finance • 8 days ago
– Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal Phase III IMforte study – – First and only combination therapy for the first-line maintenance treatment of ES-SCLC, which is critica... Full story
Yahoo Finance • 8 days ago
In recent days, Labcorp announced a collaboration with Roche to introduce FDA-cleared digital pathology slide scanners, while Roche separately unveiled the primary results for its sixth-generation high-sensitivity Troponin T test for heart... Full story
Yahoo Finance • 9 days ago
Basel, 1 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has commenced a tender offer for all of the outstanding shares of common stock of 89bio, Inc. (89bio) (NASDAQ: ETNB) at a price of $14.50 per share in cash,... Full story
Yahoo Finance • 10 days ago
Recently granted CE Mark, the novel test delivers improved sensitivity and accuracy for faster and more reliable diagnosis in emergencies.The test helps clinicians quickly identify heart attack and rule out non-cardiac causes, ensuring pat... Full story
Yahoo Finance • 11 days ago
This article first appeared on GuruFocus. Exploring the Strategic Moves in the Third Quarter of 2025 Invesco EQV European Equity Fund (Trades, Portfolio) recently submitted its N-PORT filing for the third quarter of 2025, shedding light... Full story
Yahoo Finance • 13 days ago
If you own Roche Holding stock or are weighing whether now is the right time to step in, you are not alone. The recent price action has certainly caught the eye of investors. Roche’s shares closed at 253.5, down 4.4% over the past week and... Full story
Yahoo Finance • 14 days ago
[Attorney General Garland Holds Press Conference At Justice Department] Andrew Harnik/Getty Images News U.S. President Donald Trump has demanded Microsoft (NASDAQ:MSFT [https://seekingalpha.com/symbol/MSFT]) fire Lisa Monaco, its presiden... Full story
Yahoo Finance • 14 days ago
KEY POINTS Order now: Pre-orders for ROG Xbox Ally X and ROG Xbox Ally start at 8:00 p.m. ET on September 25, 2025, in select regionsSerious gen-on-gen performance: AMD Ryzen™ AI Z2 Extreme and Z2 A processors offer exceptional gaming exp... Full story
Yahoo Finance • 16 days ago
- Ocrevus subcutaneous maintains consistent benefit-risk profile after two years - - New late-breaking data confirms Ocrevus significantly reduces disability progression in adults with advanced PPMS - - One-year data reinforce that major... Full story
Yahoo Finance • 16 days ago
OCREVUS subcutaneous maintains consistent benefit-risk profile after two years New late-breaking data confirms OCREVUS significantly reduces disability progression in adults with advanced PPMSOne-year data reinforce that majority of infant... Full story
Yahoo Finance • 17 days ago
If you have been watching Roche Holding (SWX:ROG), you might be wondering what to make of its recent run. The stock’s movement lately has caught the eye of many investors, not because of a headline-grabbing announcement or major setback, b... Full story
Yahoo Finance • 18 days ago
– evERA met its co-primary endpoints; giredestrant plus everolimus demonstrated significant benefit in ITT and ESR1-mutated populations in the post-CDK inhibitor setting, compared with standard of care plus everolimus – – The all-oral com... Full story
Yahoo Finance • 18 days ago
evERA met its co-primary endpoints; giredestrant plus everolimus demonstrated significant benefit in ITT and ESR1-mutated populations in post-CDK inhibitor setting, compared with standard of care plus everolimus The all-oral combination wa... Full story
Yahoo Finance • 21 days ago
Lunsumio provides high and long-lasting response rates, with approximately two-thirds of patients with a complete response in remission after four years1Subcutaneous Lunsumio has potential to substantially reduce treatment administration t... Full story
Yahoo Finance • 22 days ago
First mass spectrometry-based test system for total 25-Hydroxyvitamin D to receive CLIA 'Moderate Complexity' designation in the U.S. Expands access to advanced testing with a fully automated, standardized workflow on the cobas® i 601 anal... Full story